InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Frequently asked questions
What sector does InMed Pharmaceuticals Inc (INM) operate in?
InMed Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is InMed Pharmaceuticals Inc (INM) current stock price?
As of the latest data, InMed Pharmaceuticals Inc stock price is $1.59, with a previous close of $1.59.
What is InMed Pharmaceuticals Inc (INM) current market capitalization?
InMed Pharmaceuticals Inc market cap is approximately 8.74 million.
What is InMed Pharmaceuticals Inc (INM) Earnings Per Share (EPS)?
The trailing EPS is -$2.84.
What is InMed Pharmaceuticals Inc (INM) EBITDA?
InMed Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.95 million.
Does InMed Pharmaceuticals Inc (INM) pay dividends?
No. InMed Pharmaceuticals Inc does not pay a dividend.
When is InMed Pharmaceuticals Inc (INM) next earnings report?
InMed Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is InMed Pharmaceuticals Inc (INM) beta (volatility) score?
InMed Pharmaceuticals Inc has a beta of 0.978, meaning its volatility is roughly in line with the market.